IN2014CN00315A - - Google Patents
Info
- Publication number
- IN2014CN00315A IN2014CN00315A IN315CHN2014A IN2014CN00315A IN 2014CN00315 A IN2014CN00315 A IN 2014CN00315A IN 315CHN2014 A IN315CHN2014 A IN 315CHN2014A IN 2014CN00315 A IN2014CN00315 A IN 2014CN00315A
- Authority
- IN
- India
- Prior art keywords
- directed
- methods
- subject matter
- disclosed subject
- presently disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161509886P | 2011-07-20 | 2011-07-20 | |
| PCT/US2012/047453 WO2013013076A1 (en) | 2011-07-20 | 2012-07-19 | Methods of treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00315A true IN2014CN00315A (he) | 2015-04-03 |
Family
ID=47558482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN315CHN2014 IN2014CN00315A (he) | 2011-07-20 | 2012-07-19 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140221490A1 (he) |
| EP (2) | EP2734212B1 (he) |
| JP (2) | JP6320917B2 (he) |
| KR (1) | KR20140063583A (he) |
| CN (1) | CN103781484A (he) |
| AU (1) | AU2012283915B2 (he) |
| BR (1) | BR112014001335A2 (he) |
| CA (1) | CA2841964A1 (he) |
| DK (1) | DK2734212T3 (he) |
| ES (1) | ES2646226T3 (he) |
| IL (1) | IL230433A0 (he) |
| IN (1) | IN2014CN00315A (he) |
| MX (1) | MX350463B (he) |
| MY (1) | MY166036A (he) |
| NO (1) | NO2854815T3 (he) |
| WO (1) | WO2013013076A1 (he) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160033796A (ko) * | 2006-03-28 | 2016-03-28 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
| US7943591B2 (en) | 2007-05-11 | 2011-05-17 | Adynxx, Inc. | Gene expression and pain |
| EP3018122B1 (en) | 2007-11-06 | 2018-10-10 | BioElectron Technology Corporation | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EP2846839B1 (en) | 2012-05-10 | 2019-02-20 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
| PT3180434T (pt) | 2014-08-15 | 2019-10-29 | Adynxx Inc | Chamarizes oligonucleotídicos para o tratamento da dor |
| WO2017151644A1 (en) * | 2016-02-29 | 2017-09-08 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
| US20180025116A1 (en) * | 2016-07-22 | 2018-01-25 | Arizona Board Of Regents On Behalf Of University Of Arizona | Clinical Event Management and Communication System |
| US20200027555A1 (en) * | 2018-07-17 | 2020-01-23 | Lewis Pharmaceutical Information, Inc. | Patient centric drug analysis platform |
| AU2021208601A1 (en) * | 2020-02-18 | 2022-07-28 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| CN111494446B (zh) * | 2020-05-18 | 2021-08-17 | 深圳市宝安中医院（集团） | 治疗胆绞痛的中药组合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5389681A (en) | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
| IL111184A (en) * | 1993-10-08 | 2000-08-13 | Farmarc Nederland B V Of Cito | Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin |
| ZA949182B (en) | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
| WO2001098329A1 (en) | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Polyhydroxy glycopeptide derivatives |
| PL369966A1 (en) | 2002-01-15 | 2005-05-02 | Altana Pharma Ag | Pantoprazole cyclodextrin inclusion complexes |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| CN1878711B (zh) * | 2003-11-04 | 2010-12-22 | 奥蒂斯电梯公司 | 自动乘客输送机的低速运行 |
| DE602004025151D1 (de) * | 2004-03-10 | 2010-03-04 | Shimoda Biotech Pty Ltd | Stabile injizierbare Diclofenac- Zubereitungen |
| KR20090010953A (ko) * | 2006-03-28 | 2009-01-30 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형 |
| KR20160033796A (ko) * | 2006-03-28 | 2016-03-28 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
| CN101264086A (zh) | 2007-03-14 | 2008-09-17 | 南京师范大学 | 含有头孢克肟环糊精包合物的药物组合物及其制备方法 |
| WO2009089269A1 (en) * | 2008-01-07 | 2009-07-16 | Javelin Pharmaceuticals, Inc. | Methods of treating pain while minimizing adverse effects on platelet function |
| US7662858B2 (en) * | 2008-05-23 | 2010-02-16 | Aaipharma, Inc. | Method of treating post-surgical acute pain |
-
2012
- 2012-07-19 CN CN201280042680.2A patent/CN103781484A/zh active Pending
- 2012-07-19 EP EP12814382.3A patent/EP2734212B1/en not_active Not-in-force
- 2012-07-19 JP JP2014521796A patent/JP6320917B2/ja active Active
- 2012-07-19 KR KR1020147002518A patent/KR20140063583A/ko not_active Application Discontinuation
- 2012-07-19 EP EP17179857.2A patent/EP3257505A1/en not_active Withdrawn
- 2012-07-19 MX MX2014000744A patent/MX350463B/es active IP Right Grant
- 2012-07-19 CA CA2841964A patent/CA2841964A1/en not_active Abandoned
- 2012-07-19 BR BR112014001335A patent/BR112014001335A2/pt not_active Application Discontinuation
- 2012-07-19 AU AU2012283915A patent/AU2012283915B2/en not_active Ceased
- 2012-07-19 US US14/131,856 patent/US20140221490A1/en not_active Abandoned
- 2012-07-19 ES ES12814382.3T patent/ES2646226T3/es active Active
- 2012-07-19 DK DK12814382.3T patent/DK2734212T3/da active
- 2012-07-19 IN IN315CHN2014 patent/IN2014CN00315A/en unknown
- 2012-07-19 WO PCT/US2012/047453 patent/WO2013013076A1/en active Application Filing
- 2012-07-19 MY MYPI2014000142A patent/MY166036A/en unknown
-
2013
- 2013-05-30 NO NO13730377A patent/NO2854815T3/no unknown
-
2014
- 2014-01-13 IL IL230433A patent/IL230433A0/he unknown
-
2017
- 2017-01-26 JP JP2017012343A patent/JP2017110022A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017110022A (ja) | 2017-06-22 |
| KR20140063583A (ko) | 2014-05-27 |
| CA2841964A1 (en) | 2013-01-24 |
| MX350463B (es) | 2017-09-06 |
| NO2854815T3 (he) | 2018-04-21 |
| AU2012283915B2 (en) | 2016-11-24 |
| WO2013013076A1 (en) | 2013-01-24 |
| EP3257505A1 (en) | 2017-12-20 |
| ES2646226T3 (es) | 2017-12-12 |
| CN103781484A (zh) | 2014-05-07 |
| IL230433A0 (he) | 2014-03-31 |
| US20140221490A1 (en) | 2014-08-07 |
| MY166036A (en) | 2018-05-21 |
| JP6320917B2 (ja) | 2018-05-09 |
| DK2734212T3 (da) | 2017-11-06 |
| AU2012283915A1 (en) | 2014-02-06 |
| MX2014000744A (es) | 2014-05-14 |
| EP2734212A1 (en) | 2014-05-28 |
| EP2734212A4 (en) | 2014-12-24 |
| JP2014520893A (ja) | 2014-08-25 |
| BR112014001335A2 (pt) | 2017-02-21 |
| EP2734212B1 (en) | 2017-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00315A (he) | ||
| CY1121041T1 (el) | Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης | |
| NZ610034A (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| BR112014031806A8 (pt) | método para tratamento de câncer positivo para gd2 | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| NZ702730A (en) | Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments | |
| MX2014006762A (es) | Metodos para el tratamiento de desordenes cardiovasculares. | |
| MX364220B (es) | Metodos de tratamientos de fibrosis. | |
| NZ628433A (en) | Chitosan-derived compositions | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
| MX2016000220A (es) | Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| BR112012006070A2 (pt) | composições e métodos para tratar distúrbios convulsivos. | |
| MX2011007384A (es) | Terapias de combinacion para trastornos neoplásticos. | |
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| MX2014006990A (es) | Tratamiento para diabetes tipo i y tipo ii. | |
| MX2014001271A (es) | Tratamiento de diabetes de tipo 2 con fty720. | |
| RU2011143250A (ru) | Способ анестезии при хирургическом лечении косоглазия у детей | |
| NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
| MY169877A (en) | Treatment of malphigia coccigera on liver cirrhosis | |
| MX2013006633A (es) | Beta-hidroxi-gamma-aminofosfonatos para el tratamiento de trastornos inmunes. |